Rockwell Medical Signs Three-Year, Multi-Million Dollar Supply Agreement with Largest Non-Profit Dialysis Provider in the United States
WIXOM, Mich.–(BUSINESS WIRE)–Rockwell Medical, Inc. (the “Company”) (Nasdaq: RMTI), a commercial healthcare company focused on providing life-support products for patients suffering from blood disorders and kidney disorders, announced that the Company has signed an agreement signed a three-year, multi-million dollar per year product purchase agreement with the largest non-profit dialysis provider in the United States. As part of the agreement, Rockwell Medical will be the preferred supplier of liquid and dry acid and bicarbonate concentrates to this nonprofit dialysis provider’s hemodialysis facilities in the United States.
“We are pleased to have entered into this long-term agreement, which includes both supply and purchase commitments, as it will strengthen our revenue base over the next three years,” said Mark Strobeck, Ph.D., President and CEO of Rockwell Medical. “This agreement is the first of many we expect to enter into this year to grow our hemodialysis concentrate business and bring Rockwell to profitability by 2024. Hemodialysis concentrates are Rockwell’s core focus and core competencies, now more than ever committed to becoming the global leader in this market.”
In the United States, the market for in-center hemodialysis concentrates is currently valued at US$380 million and is expected to grow to approximately US$500 million by 2026, mainly driven by an increasing number of patients suffering from kidney disease in the United States end stage suffering. Rockwell is the second largest supplier of life-sustaining hemodialysis concentrate products to dialysis clinics in the United States. A vital player in this large and expanding market, Rockwell Medical is one of only two suppliers with the scalability of manufacturing and transportation infrastructure to serve the 7,500+ dialysis clinics in the United States as well as select international markets.
About Rockwell Medical
Rockwell Medical, Inc. (Nasdaq: RMTI) is a commercial healthcare company focused on providing life support products for patients suffering from blood disorders and kidney disorders. Rockwell is an innovative leader in manufacturing and supplying a portfolio of hemodialysis products, including concentrates (solutions and powders) and related supplies, to dialysis providers in the United States and internationally. Rockwell is the second largest supplier of acid and bicarbonate concentrates for dialysis patients in the United States. The company’s mission is to provide the hemodialysis community with the highest quality products, backed by the most reliable delivery service in the industry. Visit www.RockwellMed.com for more information.
Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking statements” within the meaning of the federal securities laws. Words like “may”, “could”, “will”, “should”, “believe”, “expect”, “anticipate”, “estimate”, “continue”, “might”, “might”, “would”. ,”, “develop,” “plan,” “potential,” “predict,” “forecast,” “project,” “intend,” “look forward,” “remain confident,” “are determined,” or the negative thereof Terms and similar expressions or statements regarding intentions, beliefs or current expectations are forward-looking statements. There can be no assurance that Rockwell’s hemodialysis business will grow, that Rockwell will be profitable by 2024, that Rockwell will become the world’s leading supplier of hemodialysis concentrates, that the market for in-center hemodialysis concentrates will increase in size, or that Rockwell Medical will have access to the Market will have expected market opportunities. Although Rockwell Medical believes these forward-looking statements are reasonable, you should not rely on such forward-looking statements based on information available to us as of the date of this press release. These forward-looking statements are based on current estimates and assumptions and are subject to various risks and uncertainties (including but not limited to those set forth in Rockwell Medical’s SEC filings), many of which are beyond our control and are subject to change. Actual results may differ materially. Risks and uncertainties include, but are not limited to, those risks discussed in more detail in the “Risk Factors” section of our annual report on Form 10-K for the year ended December 31, 2021, as this description may be changed or updated at any time in future reports that we file with the SEC. Rockwell Medical expressly disclaims any obligation to update our forward-looking statements, except as required by law.
